Holmes Biopharma, Inc.

Holmes Biopharma, Inc.

November 12, 2007 09:30 ET

Holmes Biopharma: Awarded Contracts Reach $10.5 Million

SCOTTSDALE, ARIZONA--(Marketwire - Nov. 12, 2007) - Holmes Biopharma, Inc. (PINK SHEETS:HLMB), announces that it has reached $10.5 million USD in awarded contracts for its Phase 1 operation in Omaha, Nebraska.

The Company is pleased in the dramatic and steady increase of sales activity from December 2006 through to October 2007. Awarded contracts have risen from $200,000 to $10.5 million USD in only ten months, a fantastic accomplishment for any company.

"We are well on our way to meeting our sales target for the first year of operation, and believe we can double sales in 2008," stated Dr. Sohail Khattak, President & CEO Qualia Clinical Service, Inc.

About Holmes:

Holmes Biopharma, Inc. and its wholly owned subsidiary, Qualia Clinical Service, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services that help the pharmaceutical industry introduce new drug products rapidly from laboratory to the market. Holmes is also actively involved in developing new drugs and drug delivery systems. Currently, clinics operate in Omaha, Nebraska, USA, Toronto, Canada and Kiev, Ukraine, Eastern Europe. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information